Table 1.
Clinical and pathological characteristics of metastatic breast cancer patients
| N | % | |
|---|---|---|
| Age at diagnosis, years | ||
| <50 | 146 | 55.5 |
| >50 | 117 | 44.5 |
| Lymph node status | ||
| Negative | 54 | 34.4 |
| 1–3 Positive | 52 | 33.1 |
| >3 Positive | 51 | 32.5 |
| Histology | ||
| Ductal | 231 | 88.2 |
| Lobular | 20 | 7.6 |
| Other | 11 | 4.2 |
| Tumour grade | ||
| 1 | 23 | 9.1 |
| 2 | 134 | 53.0 |
| 3 | 96 | 37.9 |
| Tumour size | ||
| 0–2 cm | 63 | 28.5 |
| 2–5 cm | 131 | 59.3 |
| >5 cm | 27 | 12.2 |
| Tumour subtype | ||
| ER(−) HER2(−) | 59 | 27.6 |
| ER(+) HER2(−) Ki67high | 75 | 35.0 |
| ER(+) HER2(−) Ki67low | 27 | 12.6 |
| ER(+) HER2(+) | 28 | 13.1 |
| ER(−) HER2(+) | 25 | 11.7 |
| Time to distant metastasisa | ||
| Early | 194 | 75.8 |
| Late | 62 | 24.2 |
| Multiple metastasis sites at first presentation | ||
| No | 160 | 62.7 |
| Yes | 95 | 37.3 |
| Multiple metastasis sites during follow-up | ||
| No | 50 | 19.6 |
| Yes | 205 | 80.4 |
CT chemotherapy, HT hormonal therapy, ER oestrogen receptor, PR progesterone receptor; HER2 human epidermal growth factor receptor
aCut-off point 5 years